Iran produces key cancer, antifungal drugs, cuts $6.5mn in import dependence

Iran has domestically produced three advanced drugs for cancer and acute fungal infections, reducing the country’s reliance on imports by $6.5 million, according to Saeed Sarkar, head of the Center for Strategic Technologies Development. 

Sarkar outlined the center’s mission to develop transformative technologies that strengthen national resilience and eliminate economic vulnerabilities. 

He noted that strategic technologies can serve as platforms for multiple innovations, citing the successful domestic production of petrochemical catalysts as an example of overcoming sanctions-related threats. 

Highlighting last year’s achievements, Sarkar said Iran now produces about 140 health-focused products based on modern and nanotechnologies, many of which are exported. 

Among them are two cancer drugs—“Olesta Orin” for leukemia and another for pancreatic cancer—plus an injectable antifungal medicine, all previously imported at high cost. These drugs, once priced at $800 to €1,200 per injection, are now available domestically for $25–$30 and covered by insurance, ensuring broader access to treatment. 

Sarkar also announced 20 new technology development projects for this year, including an SMA treatment, gastrointestinal cancer diagnostic kits, and other health products aimed at saving over $40 million in foreign currency.